266 related articles for article (PubMed ID: 24263233)
21. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
22. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
[TBL] [Abstract][Full Text] [Related]
23. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
24. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
[TBL] [Abstract][Full Text] [Related]
25. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
Long XH; Zhang GM; Peng AF; Luo QF; Zhang L; Wen HC; Zhou RP; Gao S; Zhou Y; Liu ZL
Oncol Rep; 2014 Jan; 31(1):328-34. PubMed ID: 24172910
[TBL] [Abstract][Full Text] [Related]
26. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
27. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
Brady SW; Zhang J; Seok D; Wang H; Yu D
Mol Cancer Ther; 2014 Jan; 13(1):60-70. PubMed ID: 24249715
[TBL] [Abstract][Full Text] [Related]
28. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
[TBL] [Abstract][Full Text] [Related]
29. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Gayle SS; Arnold SL; O'Regan RM; Nahta R
Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
[TBL] [Abstract][Full Text] [Related]
31. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
32. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells.
Mut M; Lule S; Demir O; Kurnaz IA; Vural I
Int J Biochem Cell Biol; 2012 Feb; 44(2):302-10. PubMed ID: 22085529
[TBL] [Abstract][Full Text] [Related]
33. miR-221 confers lapatinib resistance by negatively regulating p27
Huynh TK; Huang CH; Chen JY; Yao JH; Yang YS; Wei YL; Chen HF; Chen CH; Tu CY; Hsu YM; Liu LC; Huang WC
Cancer Sci; 2021 Oct; 112(10):4234-4245. PubMed ID: 34382727
[TBL] [Abstract][Full Text] [Related]
34. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
[TBL] [Abstract][Full Text] [Related]
35. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
Sambade MJ; Camp JT; Kimple RJ; Sartor CI; Shields JM
Radiother Oncol; 2009 Dec; 93(3):639-44. PubMed ID: 19853943
[TBL] [Abstract][Full Text] [Related]
37. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Wu Z; Gioeli D; Conaway M; Weber MJ; Theodorescu D
Prostate; 2008 Jun; 68(9):935-44. PubMed ID: 18386291
[TBL] [Abstract][Full Text] [Related]
38. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
[TBL] [Abstract][Full Text] [Related]
39. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
Chen CH; Hsia TC; Yeh MH; Chen TW; Chen YJ; Chen JT; Wei YL; Tu CY; Huang WC
Mol Oncol; 2017 Sep; 11(9):1273-1287. PubMed ID: 28632938
[TBL] [Abstract][Full Text] [Related]
40. [Evodiamine induces extrinsic and intrinsic apoptosis of ovarian cancer cells via the mitogen-activated protein kinase/phosphatidylinositol-3-kinase/protein kinase B signaling pathways].
Wei L; Jin X; Cao Z; Li W
J Tradit Chin Med; 2016 Jun; 36(3):353-9. PubMed ID: 27468551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
